Research programme: antioxidants - Abiogen PharmaAlternative Names: Antioxidants - Abiogen Pharma; CNS disorders therapeutics - Abiogen Pharma; CRAM 1-2
Latest Information Update: 19 Jul 2010
At a glance
- Originator Abiogen Pharma
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 19 Jul 2010 Preclinical development is ongoing in Italy
- 18 Mar 2008 Preclinical trials in CNS disorders in Italy (unspecified route)